linjc16/ctgov huggingface dataset:
UVB-Induced MVP Release in Human Skin

Study Overview
=================
Brief Summary
-----------------
This study is designed to assess if ultraviolet B radiation (UVB) found in sunlight causes the release of microvesicle particles in human skin, and if antioxidant vitamins can block their production.

Official Title
-----------------
Ultraviolet B Radiation-Induced Microvesicle Particle Release in Human Skin

Conditions
-----------------
Ultraviolet B Radiation, Microvesicle Particles

Intervention / Treatment
-----------------
* Dietary Supplement: Vitamin C
* Dietary Supplement: Vitamin E


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male subjects Ages 21 to 45 Skin type: Fitzpatrick Type I or II Exclusion Criteria: Have underlying diseases that could affect wound healing On medications that are known photosensitizers (e.g., doxycycline) or anti-inflammatories (e.g., NSAIDS [except for low-dose aspirin] or steroids) History of abnormal scarring (e.g., keloids) Should not be on Vitamin C or E supplements for past month Unable to understand/complete informed consent Large volar arm tattoos that would inhibit the ability to conduct/evaluate the skin testing Renal compromise/kidney stones or allergy to Vitamin C/Vitamin E or lidocaine anaesthetic Use of tanning bends or recent UVB exposure to the areas in the past 3 months Recent (within 1 week) use to sunscreen to volar forearms

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Vitamin C & Vitamin E<br>After subjects undergo UVB treatment then they will be instructed to take two Vitamin C and one Vitamin E tablets daily for 8 days. | Dietary Supplement: Vitamin C<br>* Two Vitamin C tablets daily for 8 days.<br>Dietary Supplement: Vitamin E<br>* One Vitamin E tablet daily for 8 days.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in microvesicle particles (MVP) levels from baseline | Levels of microvesicle particles will be determined from skin biopsies | Day 8 |
Prevalence of Tattoos and Piercings in Healthcare Using the Example of Obstetrics Workers

Study Overview
=================
Brief Summary
-----------------
Tattoos and piercings as body decorations have developed into an art form over the last few decades and its social recognition is growing. However, critics also speak of an excessive lifestyle when tattooing or piercing. The data from the questionnaires should examine how widespread tattoos and piercings are among medical staff and thus make a statement on acceptance.

Official Title
-----------------
Prevalence of Tattoos and Piercings in Healthcare Using the Example of Obstetrics Workers (TattOBS)

Conditions
-----------------
Acceptance, Social

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: medical stuff in obstetrics minimum 18 years old Exclusion Criteria: language barrier uncompleted questionnaire

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| medical stuff in obstetrics<br>medical doctors, nurses, midwives | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of tattoos and piercings in healthcare using the example of obstetrics workers | Measurement of self-reported tattoos and piercings by a questionnaire | 3 months |
Performance of Whole Body MRI in Extraplevic Disease Detection in Patients Undergoing Pelvic Exenteration for Gynecological Maligniancies

Study Overview
=================
Brief Summary
-----------------
The aim of this prospective observational diagnostic study is to investigate the diagnostic accuracy od extrapelvic disease detection using Whole-body-MRI (WB-MRI) in patients with gynecologic cancer candidate to the pelvic exenteration.

Official Title
-----------------
Performance of Whole Body MRI in Extraplevic Disease Detection in Patients Undergoing Pelvic Exenteration for Gynecological Maligniancies

Conditions
-----------------
Gynecologic Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years Written Informed Consent All patients with recurrent gynecological cancer that are planned to undergo pelvic exenteration or laterally extended pelvic resection, both with curative and palliative intent Patients considered fit for srugery Exclusion Criteria: Controindication to MRI (Claustrophobia, implanted ferromagnetic materials or foreign objects, Known intolerance or controindication to the MRI contrast agent, cardiac pacemaker) Individuals who are not able or willing to tolerate the required prologed stationary supine position during examination (approximately 40-60 minutes) Patient unable to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of diagnostic accuracy for extrapelvic disease detection using whole-body MRI |  | Through study completion, an average of 2 yearS | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Agreement between WB-MRI and PET-CT in detecting extrapelvic involvement |  | Through study completion, an average of 2 yearS |
Preoperative Serum FGF19 in the Prognosis of Biliary Atresia

Study Overview
=================
Brief Summary
-----------------
To investigate the role of preoperative serum FGF19 level in the prognosis of biliary atresia.

Detailed Description
-----------------
Kasai portoenterostomy is currently one of the main treatment methods for biliary atresia, but about 30% of children still require liver transplantation even after receiving the surgery. Accurate prognosis will help select the most suitable treatment method for children, but there is currently a lack of effective preoperative predictive indicators. Serum FGF19 has recently been considered a possible preoperative predictive indicator for biliary atresia, but its predictive value has not been confirmed in a large sample and in Asian population, thus the investigators try to further explore the prognostic value of serum FGF19 in children with biliary atresia based on a large sample.

Official Title
-----------------
Preoperative Serum FGF19 in the Prognosis of Biliary Atresia

Conditions
-----------------
Biliary Atresia, Prognosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Samples diagnosed as biliary atresia in Children's Hospital of Fudan University Samples with one-year follow-up records after surgery Samples with a record of serum total bilirubin levels three months after surgery Samples with preoperative serum left（volume > 500ul) Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Good prognosis + Poor prognosis<br>Good prognosis: the serum total bilirubin level was less than 20 umol/l three months after surgery, and no liver transplantation or death occurred within a year after surgery. Poor prognosis: the serum total bilirubin level was higher than 20 umol/l three months after surgery, and no liver transplantation or death occurred within a year after surgery. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum total bilirubin level (umol/l) | The difference of serum total bilirubin level will be measured with ELISA( Enzyme Linked ImmunoSorbent Assay) three months after surgery | Three months after surgery | 
| Native liver survival (%) | The difference of native liver survival will be measured according to the follow-up statue one year after surgery | One year after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Biliary Atresia, FGF19
Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer

Study Overview
=================
Brief Summary
-----------------
This is a prospective study to establish the analytical specificity of Bladder EpiCheck test in urine samples from healthy population and urology patients without prior history or evidence of bladder cancer.

Official Title
-----------------
Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer

Conditions
-----------------
Non Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma

Intervention / Treatment
-----------------
* Diagnostic Test: Bladder EpiCheck


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 22 or older Able to sign the informed consent form Normal, healthy subjects or subjects with one of the following conditions: Benign non-genitourinary disease (e.g. heart disease) Non-genitourinary cancers (e.g. lung, CRC, breast) Genitourinary disease other than bladder cancer including: Benign prostatic hyperplasia (BPH) Microhematuria proven negative for bladder cancer through prior UCC evaluation Inflammation/infection Symptomatic sexually transmitted disease (STD) Urinary tract stones Genitourinary trauma Subjects with native bladder Exclusion Criteria: Known current or prior diagnosis of bladder cancer (non-muscle or muscle invasive) Currently in work-up due to suspicion of cancer of any kind

Ages Eligible for Study
-----------------
Minimum Age: 22 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy<br>Healthy subjects and urology patients without prior history or evidence of bladder cancer | Diagnostic Test: Bladder EpiCheck<br>* Bladder EpiCheckTM (EpiCheck) is a urine test for monitoring of recurrence of NMIBC based on analysis of 15 informative DNA methylation biomarkers.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Specificity | The primary endpoint of the study is the specificity of the Bladder EpiCheck Test in healthy population. | Day 1 |
Immune Function and the Progression to T1D

Study Overview
=================
Brief Summary
-----------------
To elucidate the mechanisms by which type 1 diabetes-associated genes; IFIH1, TYK2, IKZF4, as well as total genetic risk, impart functional immunoregulatory abnormalities that result in expansion of self-reactive adaptive immune cells, defective regulatory/effector mechanisms in T cells, inflammatory antigen presenting cells, and abnormal immune function in T cells and B cells.

Detailed Description
-----------------
Newly proposed studies will identify the inflammatory cues that draw immune cells into islets for disease initiation (Project 1); probe the motility of immune cells through inflamed vasculature to the target organ and antigen priming sites within secondary lymphatics (Project 2); and characterize the T1D-associated adaptive immune signatures in blood and immune tissues (Project 3). The overall hypothesis of the renewed P01 states: 1) the impact of T1D-risk variants will vary by tissue, cell subset, and activation state, and 2) risk variants, cellular stress, and defects in immunologic pathways are key to engender the autoimmune destruction of pancreatic B-cells that results in T1D.

Official Title
-----------------
Immune Function and the Progression to Type 1 Diabetes:

Conditions
-----------------
Type 1 Diabetes

Intervention / Treatment
-----------------
* Other: blood draw


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: able to have blood drawn - Exclusion Criteria: none -

Ages Eligible for Study
-----------------
Minimum Age: 0 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Subjects with diabetes age 0 to 100 years<br>People who have not been diagnosed with type 1 diabetes | Other: blood draw<br>* a peripheral blood draw<br>|
| Subjects with type 1 diabetes age 0 to 100 years<br>People who have been diagnosed with type 1 diabetes | Other: blood draw<br>* a peripheral blood draw<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the number of participants who become at risk for development of type 1 diabetes | the number of participants who become at risk for development of type 1 diabetes | through study completion, up to 25 years | 
| Genetic risk of type 1 diabetes | the number of people in different genetic risk groups who develop type 1 diabetes | through study completion, up to 25 years |
Evaluation of a Novel Amino Acid Based Moisturizing Cream as Part of the Daily Standard Skincare Regimen Recommended During Radiation Therapy

Study Overview
=================
Brief Summary
-----------------
The goal of this clinical study is to evaluate a novel amino acid based moisturizing cream as part of the daily standard skincare regimen recommended during radiation therapy. The main aim of this study is to assess if the investigational product can improve skin redness associated with radiation therapy. Participants will apply a moisturizer daily during the course of their prescribed radiation therapy for breast cancer. Researchers will compare against the standard of care.

Official Title
-----------------
Evaluation of a Novel Amino Acid Based Moisturizing Cream as Part of the Daily Standard Skincare Regimen Recommended During Radiation Therapy

Conditions
-----------------
Erythema, Radiation Therapy, Secondary Skin Reactions

Intervention / Treatment
-----------------
* Other: VS-200Cr
* Other: Standard of care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Provision of signed and dated informed consent form. Aged over 18 years old. Has been diagnosed with breast cancer and prescribed radiotherapy as a part of their cancer treatment. Planned radiotherapy, as prescribed by the oncologist, is expected to provide a total radiation dose of up to 60 gray within the first 4 weeks of treatment. Be able to adhere to proposed daily wound/site care as proposed by the protocol in line with the AADs recommendations. Exclusion Criteria: Pre-existing skin conditions which in the opinion of the investigator could impact on the integrity of the study or compromise the safety of the patient (i.e., active eczema, psoriasis, or an open wound over the planned site of radiation). Have a concurrent medical condition or poor functional baseline which in the opinion of the investigator would make them unsuitable or able to fully comply with the study protocol. Are pregnant or actively breast feeding. Known allergic reactions to ingredients of the Investigational Product or the Standard of Care.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sham Comparator: Standard of Care<br>Standard of Care | Other: Standard of care<br>* AAD recommended course of care.<br>|
| Active Comparator: Investigational Product<br>Investigational product | Other: VS-200Cr<br>* Topical cream with moisturizing factors.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction in Erythema | Evaluation of skin redness (both severity and size) with ScarletRed technology | Up to 12 weeks |
Pre-operative 5% Dextrose Infusion & PONV

Study Overview
=================
Brief Summary
-----------------
With this study, we aim to compare the efficacy of pre-operative dextrose-containing fluid infusion with other fluid for the prevention of PONV in middle ear surgeries.

Detailed Description
-----------------
We hypothesized that maintenance of stable level of blood glucose in addition to adequate hydration through preoperative intravenous dextrose 5% infusion will have a rule in decreasing the incidence and severity of PONV; as it reduces insulin resistance and decreases gastric acid secretion; which may contribute to PONV.

Official Title
-----------------
Is Pre-operative Infusion of 5% Dextrose Effective in Reducing the Incidence of PONV in Middle Ear Surgery? A Blinded Randomized Control Trial

Conditions
-----------------
Nausea, Postoperative

Intervention / Treatment
-----------------
* Dietary Supplement: Dextrose 5%, normal saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA physical status I and ll. Patients undergoing middle ear surgeries, mastoidectomy, or tympanoplasty Exclusion Criteria: history of dependence or use of antiemetics history of motion sickness presence of psychiatric illness pregnant and lactating women cardiovascular disorders (Ischemic heart diseases, congestive heart failure and valvular diseases) Diabetic patients

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control group<br>Patients will be fasted and not receiving any pre-operative fluids | |
| Active Comparator: Dextrose group<br>Patients will take 100ml/HR of clear fluids (apple juice) during the fasting hours till 2 hrs before the operation and will receive dextrose 5% infusion at a rate of 1ml/kg/h 2hrs before the operation and till the end of the operation | Dietary Supplement: Dextrose 5%, normal saline<br>* Decrease fasting hours<br>|
| Placebo Comparator: Normal saline group<br>Patients will take 100ml/HR of water during the fasting hours till 2 hrs before the operation and will receive normal saline 0.9% at a rate of 1ml/kg/h (group NS) intravenously (IV)2hrs before the operation and till the end of the operation | Dietary Supplement: Dextrose 5%, normal saline<br>* Decrease fasting hours<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PONV | incidence | 24 hours |
Plaque Burden and Ischemia in MINOCA

Study Overview
=================
Brief Summary
-----------------
The goal of this clinical trial is to assess coronary artery plaque burden, perivascular inflammation and extent of myocardial ischemia in patients presenting with acute myocardial infarction and non-obstructive coronary artery disease. The main question it aims to answer are: Identify coronary artery anatomy, plaque burden, composition and high-risk plaque features by CT coronary angiography in MINOCA Assess presence, extent and severity of myocardial ischemia in MINOCA Participants will examined by CT coronary angiography and stress [12N] NH3 PET-MR.

Official Title
-----------------
Coronary Artery Plaque, Perivascular Inflammation and Myocardial Ischemia in Patients With Myocardial Infraction and Non-obstructive Coronary Arteries

Conditions
-----------------
MINOCA

Intervention / Treatment
-----------------
* Diagnostic Test: CT coronary angiography and [12N] NH3 PET-MR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acute chest pain Elevated troponin Non-obstructive coronary arteries by coronary angiography Exclusion Criteria: Obstructive coronary artery disease Contraindications against CT coronary angiography or stress [12N] NH3 PET-MR Not able to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CT coronary angiography and [12N] NH3 PET-MR<br>All patients will undergo CT coronary angiography and stress [12N] NH3 PET-MR | Diagnostic Test: CT coronary angiography and [12N] NH3 PET-MR<br>* Advanced coronary artery plaque analysis, myocardial ischemia and coronary flow reserve<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plaque burden |  | 1 week | 
| Myocardial ischemia |  | 1 week |